A Novel PDX Model to Evaluate FL-HCC Therapies

Fibrolamellar hepatocellular carcinoma (FL-HCC) is a rare and distinct primary hepatic malignancy, which has recently been recognized as a distinct clinical entity from HCC with respect to its epidemiology and prognosis.